Altheia Science Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
4
Altheia Science General Information
Description
Developer of cell and gene therapeutics designed for the treatment of autoimmune diseases and liquid tumours. The company focuses on modulating the expression of PD-L1 on patients' hematopoietic stem and progenitor cells, restoring their therapeutic immune ability and eliminating autoreactive T lymphocytes along with novel tumor-specific antigens for CAR-T cells, enabling healthcare organizations to target the elimination of leukemic cells while sparing healthy ones.
Contact Information
Website
www.altheiascience.comCorporate Office
- Via Conservatorio, 30
- 20122 Milan
- Italy
Corporate Office
- Via Conservatorio, 30
- 20122 Milan
- Italy
Altheia Science Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC | 31-Mar-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 19-Dec-2018 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | 01-Jan-2017 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Altheia Science Patents
Altheia Science Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023194501-A1 | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens | Inactive | 05-Apr-2022 | ||
| CA-3216175-A1 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens | Pending | 05-Apr-2021 | ||
| WO-2022214499-A3 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens | Inactive | 05-Apr-2021 | ||
| WO-2022214499-A9 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens | Inactive | 05-Apr-2021 | ||
| WO-2022214499-A2 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigenscross-reference to related applications | Inactive | 05-Apr-2021 | C07K16/2896 |
Altheia Science Signals
Altheia Science Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advanced Accelerator Applications | Corporation | Minority | ||
| Fin Posillipo | Corporation | Minority | ||
| Rottapharm Biotech | Corporation | Minority | ||
| Università degli Studi di Milano Statale | University |
Altheia Science FAQs
-
When was Altheia Science founded?
Altheia Science was founded in 2017.
-
Where is Altheia Science headquartered?
Altheia Science is headquartered in Milan, Italy.
-
What is the size of Altheia Science?
Altheia Science has 6 total employees.
-
What industry is Altheia Science in?
Altheia Science’s primary industry is Biotechnology.
-
Is Altheia Science a private or public company?
Altheia Science is a Private company.
-
What is Altheia Science’s current revenue?
The current revenue for Altheia Science is .
-
How much funding has Altheia Science raised over time?
Altheia Science has raised $19.3M.
-
Who are Altheia Science’s investors?
Advanced Accelerator Applications, Fin Posillipo, Rottapharm Biotech, and Università degli Studi di Milano Statale have invested in Altheia Science.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process